GMED vs HOLX Stock Comparison
Compare GMED and HOLX across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between GMED and HOLX?
GMED and HOLX are close on the current AIQ evidence, so the better fit depends more on objective, risk tolerance and valuation preference than on a single headline score.
AlgovestIQ AIQ Comparison
Globus Medical, Inc. vs Hologic, Inc.
GMED and HOLX are effectively level
GMED and HOLX are effectively level on the AIQ Score; the factor table below shows where each one holds its advantage.
Globus Medical, Inc.
Hologic, Inc.
The Algovestiq AIQ Score does not currently separate GMED and HOLX as of Sep 12, 2026. Both names are scored on the same 0–100 scale across Quality, Value, Momentum and Risk Resilience, and the factor table below shows where each one holds its advantage.
Compare Globus Medical, Inc. and Hologic, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare GMED and HOLX against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Value55 vs 37GMED +18
- Quality71 vs 58GMED +13
- Risk Resilience74 vs 81HOLX +7
Neither name separates cleanly on the covered dimensions.
What changed since the last close
Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.
No factor moved materially.
No new signals fired.
No factor moved materially.
No new signals fired.
Deeper signal detail for each name lives on its own signals page — GMED and HOLX both carry a full feed there.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
EvenNeither separates on the overall score.
Growth
GMEDGMED on combined revenue and EPS growth.
Value
GMEDGMED on the peer-relative Value factor, by 18 points.
Momentum
EvenThe two are level on Momentum.
Lower downside
HOLXHOLX on Risk Resilience, by 7 points.
Analyst upside
GMEDGMED on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | GMED | HOLX | Note |
|---|---|---|---|
| Implied upside to target | +33.3% | +3.9% | GMED has more room |
| Target dispersion | +37.4% | 0% | Lower is tighter analyst agreement |
| Consensus | Buy | Hold | Context, not a primary driver |
| Analysts covering | 8 | 1 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
How each independent group of evidence reads the pair.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | Even | 54 vs 54 |
| Fundamentals | GMED | EPS growth 21.7% vs -4.8%; TTM ROE 11.6% vs 11%; gross margin 68.5% vs 52.8%; operating margin 20.8% vs 17.5% |
| Valuation | GMED | Value 55 vs 37 |
| Technicals | HOLX | Price vs 50-day -7.8% vs 1%; vs 200-day -13.1% vs 6.7% |
| Risk Resilience | HOLX | Risk Resilience 74 vs 81 |
| Analyst expectations | GMED | Target upside 33.3% vs 3.9% |
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 0 points. (argues the conclusion is provisional)
- Only 1 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
How the comparison changed
119 daily snapshots · May 4 – Sep 10GMED lead: Weakening — the AIQ differential moved from 14 to 0 points over 30 sessions.
- Today
- Level
- 54 vs 54
- 7 sessions ago
- Level
- 54 vs 54
- 30 sessions ago
- GMED +14
- 68 vs 54
- 90 sessions ago
- GMED +3
- 57 vs 54
The lead changed hands once in this window, most recently on May 8 when HOLX moved ahead of GMED.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
1 bullish / 4 bearish, conflicted
- Death Cross Active — bearish, trend, long horizon (6.59%)
- Keltner Channel Breakdown — bearish, volatility, short horizon
- RSI Oversold - Potential Bounce — bullish, momentum, short horizon
No active signals
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.86%, AIQ 0 points).
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
GMED leads on balance| Metric | GMED | HOLX |
|---|---|---|
| Revenue growth (YoY) | 3.9% | -0.2% |
| EPS growth (YoY) | 21.7% | -4.8% |
| Gross margin | 68.5% | 52.8% |
| Operating margin | 20.8% | 17.5% |
| Return on equity (TTM) | 11.6% | 11% |
| Debt to equity | 0.02 | 0.48 |
Performance
HOLX leads 6 of 6 windows| Metric | GMED | HOLX |
|---|---|---|
| 1 week (5 sessions) | -8.8% | 0.4% |
| 1 month (20 sessions) | -14.1% | 0.4% |
| 3 months (63 sessions) | -9% | 1.9% |
| 6 months (126 sessions) | -15.6% | 13.4% |
| Year to date | -13.6% | 2% |
| 1 year (252 sessions) | 23.5% | 23.8% |
Technicals
HOLX has the stronger structure| Metric | GMED | HOLX |
|---|---|---|
| RSI (14) | 15.2 | 77.2 |
| ADX (14) | 22 | 18.6 |
| Price vs 50-day | -7.8% | 1% |
| Price vs 200-day | -13.1% | 6.7% |
| Volatility (1M, annualized) | 27.2% | 3% |
Risk
HOLX is the more resilient| Metric | GMED | HOLX |
|---|---|---|
| Beta | 0.78 | 0.07 |
| Sharpe ratio | 0.59 | 1.05 |
| Sortino ratio | 1.34 | 1.56 |
| Max drawdown | -24% | -8.2% |
| Current drawdown | -24% | 0% |
| Annualized volatility | 49% | 16% |
| Value at risk (95%) | -3.1% | -1.3% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which has more analyst upside, GMED or HOLX?
Analyst price targets imply +33.3% upside for GMED and +3.9% for HOLX, so the Street currently favors GMED. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, GMED or HOLX?
GMED is the better-valued of the two on the peer-relative Value factor. GMED on the peer-relative Value factor, by 18 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, GMED or HOLX?
GMED on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, GMED or HOLX?
The two are level on Momentum. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, GMED or HOLX?
HOLX is the more resilient of the two, so the other name carries the higher downside risk. HOLX on Risk Resilience, by 7 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is GMED more profitable than HOLX?
GMED leads on the comparable margin measures — gross margin 68.5% vs 52.8%; operating margin 20.8% vs 17.5%; ttm roe 11.6% vs 11%.
What do the current signals say about GMED and HOLX?
GMED: 1 bullish / 4 bearish, conflicted. HOLX: No active signals. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on GMED is Death Cross Active (bearish, long horizon).
Compare GMED and HOLX with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.